Evotec

Join us at #PEGSEurope! Our experts will present two poster presentations: MytomAb: Multi-specific cytotoxicity maximizing antibodies for cancer immunotherapy CD2 BiTco: Novel CD2-targeted Bispecific T cell co-stimulators for cancer immunotherapy Visit our events page to set up a meeting with them in Barcelona- https://hubs.ly/Q02W7Df_0 We are looking forward to seeing you there! #CancerImmunoTherapy #Oncology

We are excited to be heading to Stockholm next week for this year's BIO-Europe! Our experts will be in attendance to discuss Evotec's drug discovery and development solutions. You can find us at booth #59. Bernd Muehlenweg, SVP, Head of Global Business Development, Cell Therapy, will be participating in the cell and gene therapy panel - “Under Attack”: Can cell & gene therapy revolutionize the rules of healthcare? on 5 November at 4:00pm CET in room K2. Tim James, VP Head of in silico R&D, will be participating in the panel - "I Have a Dream" AI for Drug Discovery on 5 November at 4:00pm CET in room K1. Learn more about the panels, register or contact us to arrange a meeting at BIO-Europe here- https://hubs.ly/Q02VZTxP0 #BIOEurope #DrugDiscovery #DrugDevelopment #CellTherapy #GeneTherapy

Join us for our upcoming webinar, Drugging the Gut Microflora to Reduce Drug Toxicity, hosted by Technology Networks, where we will explore how gut bacteria influence drug metabolism and potential toxicity. Date: 6th November 2024 Time: 4pm GMT | 5pm CET | 11am EST | 8am PST Host: Technology Networks Registration link:https://hubs.ly/Q02VHFJV0 #researchneverstops #cyprotex #webinar

Evotec is excited to participate in the upcoming IBIG (Italian Biostatistics Group) Forum, taking place from 29 - 31 October at Chiesi's headquarters in Parma. Our team will be involved both as moderators and speakers, contributing our expertise to this important event. On 29 October, Andrea Nizzardo, Manager of Clinical Biometry, Pharmacometrics, Clinical Development & Translational Medicine, will moderate the pre-forum course on "Optimizing ADaM CDISC Datasets for the Implementation of the Estimands Framework," a critical topic in advancing data standards within the E9(R1) Estimands Framework. Additionally, on 31 October, Luca Genetti, Associate Biostatistician, will present on the design and analysis of early-phase studies, where he will showcase our internally developed dose escalation model for oncology studies. His presentation, titled “Extending the Bayesian Logistic Regression Model Integrating non-DLT Adverse Events,” highlights our innovative approach to early-phase clinical research. We look forward to meaningful discussions and collaborations at IBIG 2024! Learn more or schedule a meeting with us at IBIG here- https://hubs.ly/Q02VCtm20 #Biostatistics #ClinicalResearch #Oncology #Pharma #Innovation #IBIG2024 #Evotec

We’re thrilled to introduce our PanOmics TargetID Framework, a cutting-edge modular system designed by our Bioinformatics and Computational Biology teams. This innovative framework leverages advanced computational tools and expert assessments to identify and rank potential drug targets, providing a comprehensive report on their draggability, biology, safety, competition, and efficacy. Key Highlights: - Comprehensive Target Identification: Discover and validate disease-associated molecular mechanisms. - Expert Assessments: Detailed insights into target draggability, biology, safety, and more. - Modular System: Flexible and adaptable to various research needs. Download our whitepaper to learn more about how we’re revolutionizing drug discovery: https://hubs.ly/Q02T7lQ00 #DrugDiscovery #Bioinformatics #PanOmics #researchneverstops

How can we design better antibodies to support global health initiatives and expand access to biotherapeutics? In our upcoming roundtable on Antibody Design to Support Global Health Initiatives we will focus on the innovative field of antibody design and its critical role in advancing global health. The virtual roundtable will bring together leading experts to discuss cutting-edge research, technological advancements, and collaborative efforts aimed at tackling some of the world’s most pressing health challenges. Date: 5 December 2024 Time: 17:00 CET | 08:00 PST | 11:00 EST | 16:00 BST Location: Virtual Key Topics: • Strategies for developing effective therapeutics with AI and ML • The latest advancements in antibody engineering • Collaborative efforts to address global health issues Don’t miss this opportunity to gain insights from industry leaders and network with professionals dedicated to improving global health through innovative antibody design. Register now- https://hubs.ly/Q02VsSJy0 #GlobalHealth #AntibodyDesign #Biotech #Innovation #Healthcare

Evotec SE announced progress within the company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a program-based payment of US$ 50 m to Evotec. Based on potential program-based milestones, the expansion contributes to the deal value. Read the full press release to learn more- https://hubs.ly/Q02Vq_DQ0 #TogetherForMedicinesThatMatter #MolecularGlueDegraders #Proteomics

We are proudly sponsoring this year's Stem Cell Derived Islets - 5th IPITA/HSCI/Breakthrough T1D Summit. Taking place in Boston, USA from 28-29 October, this is set to be a brilliant event, featuring most recent scientific breakthroughs and leading experts in the field of stem cell-derived islet biology. Our VP iPSC Cell Therapy, Audrey Holtzinger will be in attendance - be sure to say hello and find out more about Evotec's activities in the space of iPSC-derived cell therapies for diabetes treatment. Get in touch: https://hubs.ly/Q02Vjk0F0 #StemCells #CellTherapy #iPSC #IPITA #diabetes

We are proud to have recently wrapped up a successful PhD Day at Evotec, where PhD students collaborating with or sponsored by us had the opportunity to showcase their cutting-edge research. A big thank you to all the students who presented in the following sessions: AI for Computational Biology AI for Protein Dynamics Advances in MD-Based Methods AI for Chemistry We also want to extend our appreciation to our university collaborators for their valuable contributions. It’s exciting to see the progress being made, and we look forward to continuing these collaborations towards medicines that matter. #TogetherForMedicinesThatMatter #PhD

We are proud to share and congratulate Julian Reinard, Machine Learning Scientist at Evotec, for his recent first place in the Biomarkers of Aging Challenge: Chronological Age Prediction. The aim of the Aging Challenge is to develop and compare the best prediction models for chronological age, mortality and multimorbidity. The challenge utilizes a unique, high-quality dataset that includes DNA methylation and aging data from over 500 different individuals. DNA methylation and other first-generation biomarkers of aging are often trained to predict chronological age. Discrepancies between predicted and actual age (prediction errors) may indicate a “higher” or “lower” biological age associated with age-related health outcomes, including mortality. You can learn more about the work our scientists like Julian are doing everyday in biomarkers here- https://hubs.ly/Q02TSgwg0 #Biomarkers #TogetherForMedicinesThatMatter #Aging